Alzheimer's Disease Agitation Data - NMRA-511 demonstrated a favorable safety profile with no somnolence or sedation and significant improvements in agitation, with placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, respectively [2] - Patients with elevated anxiety showed improvements of -7.6 and -5.6 at the same weeks [2] - William Blair projects peak U.S. sales of NMRA-511 to reach $1.8 billion, indicating promising early data despite previous setbacks with the V1a receptor antagonist approach [2] Obesity Update - Positive Phase 2 data for NMRA-215 in obesity is anticipated by year-end 2026, which could be a significant inflection point for Neumora [3] - William Blair has incorporated value into the Neumora model for NMRA-215, estimating a 15% probability of success that could unlock a market opportunity exceeding $2 billion under conservative assumptions [3] Depression Assets - The KOASTAL-2/3 trials of monotherapy navacaprant in major depressive disorder are expected to report results in the second quarter of 2026 [4] - There is intrigue surrounding the update in the KOR antagonist space, although caution is advised regarding the de-risking value of navacaprant [4] - NMRA stock experienced a 7.50% increase, reaching $3.45 at the last check [4]

Core Insights - AbbVie has announced a deal to acquire Gilgamesh Pharmaceuticals' lead pipeline candidate, bretisilocin, which is being developed for treating major depressive disorder (MDD) [1][8] Group 1: Deal Details - AbbVie will pay up to $1.2 billion for the acquisition, which includes an upfront payment and development milestones [6][8] - Gilgamesh will spin off its other drug programs into a new company, Gilgamesh Pharma, while AbbVie retains full control of bretisilocin [6][7] Group 2: Clinical Data - Bretisilocin is currently in a phase II study for moderate-to-severe MDD, showing rapid and durable antidepressant effects [2][8] - In the phase II study, bretisilocin led to a statistically significant reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score, with patients improving by an average of 21.6 points compared to 12.1 points for the comparator at Day 14 [2] Group 3: Market Context - AbbVie has been actively acquiring companies to strengthen its early-stage neuroscience pipeline, with recent deals including the acquisition of Aliada and Cerevel Therapeutics [9][10] - AbbVie's neuroscience portfolio has seen significant growth, with sales increasing by 20.3% to around $5 billion in the first half of 2025, driven by products like Botox Therapeutic and Vraylar [11]